Navtemadlin is under clinical development by Kartos Therapeutics and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Navtemadlin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Navtemadlin is under development for the treatment of relapsed or refractory small cell lung cancer, primary myelofibrosis, polycythemia vera, post-polycythemia vera myelofibrosis (PPV-MF), relapsed/refractory diffuse large B-cell lymphoma or relapsed/refractory chronic lymphocytic leukemia, endometrial cancer, chronic myelocytic leukemia, Merkel cell carcinoma, post-essential thrombocythemia myelofibrosis (Post-ET MF) and relapsed and refractory acute myeloid leukemia, soft tissue sarcoma, liposarcoma, metastatic breast cancer and non-small cell lung cancer. The drug candidate is administered through oral route as tablet. It acts by targeting murine double minute 2 (Mdm2).
It was also under development for relapsed, refractory multiple myeloma, metastatic cutaneous melanoma, glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (GBM).
Kartos Therapeutics overview
Kartos Therapeutics is a clinical stage biopharmaceutical company dedicated to the development of novel, targeted therapeutics. Kartos Therapeutics is headquartered in Redwood City, California, the US.
For a complete picture of Navtemadlin’s drug-specific PTSR and LoA scores, buy the report here.